Puma | pharmaphorum

Skip to main content

Sunday 16 March 2025

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Puma

News

Radiology technician examens mammography test on location

EU regulators reject Puma's Nerlynx breast cancer drug

European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.

News

Radiology technician examens mammography test on location

MacroGenics' HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g

News

trump_kentucky

Trump tax reform uncertainty puts biotech M&A on hold

Tesaro and Puma are potential takeover targets

News

Radiology technician examens mammography test on location

Victory for Puma as FDA approves breast cancer drug

Neratinib can be used to reduce risk of disease returning.

News

Roche Rituxan approval

Puma gains as Roche breast cancer combo disappoints

ASCO serves up shock as Roche's data disappoints

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA advisers back Puma breast cancer drug despite safety wor...

But biotech still has several hurdles to clear - including Roche's rival.

Load more results

Editor's Picks

NICE agrees to look again at Alzheimer's drug Leqembi

Bayer CEO warns of tough 2025 as turnaround plan beds in

Sofinnova raises €1.2bn to back 'up to 60' companies

Roche ends the 30-year US hiatus in new stroke drugs

AbbVie pays Gubra $350m upfront to enter obesity field

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Abstract visual of head

Sponsored

Health Trends 2025: Reimagining What's Possible

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company